Screening Patient Misidentification Errors Using a Deep Learning Model of Chest Radiography: A Seven Reader Study.

J Imaging Inform Med

Department of Convergence Medicine, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea.

Published: September 2024

AI Article Synopsis

  • A study was conducted to assess how well deep learning (DL) models could identify patients using paired chest radiographs (CXRs) and compare their accuracy to human radiologists.
  • The DL models were trained on a large dataset of over 240,000 CXRs and tested on various populations, while the performance of the models was compared against junior and senior radiology residents and expert radiologists.
  • The results showed that the SimChest DL model performed similarly to the radiologists in identifying patients, with an accuracy indicating that DL models can effectively screen for patient misidentification alongside human experts.

Article Abstract

We aimed to evaluate the ability of deep learning (DL) models to identify patients from a paired chest radiograph (CXR) and compare their performance with that of human experts. In this retrospective study, patient identification DL models were developed using 240,004 CXRs. The models were validated using multiple datasets, namely, internal validation, CheXpert, and Chest ImaGenome (CIG), which include different populations. Model performance was analyzed in terms of disease change status. The performance of the models to identify patients from paired CXRs was compared with three junior radiology residents (group I), two senior radiology residents (group II), and two board-certified expert radiologists (group III). For the reader study, 240 patients (age, 56.617 ± 13.690 years, 113 females, 160 same pairs) were evaluated. A one-sided non-inferiority test was performed with a one-sided margin of 0.05. SimChest, our similarity-based DL model, demonstrated the best patient identification performance across multiple datasets, regardless of disease change status (internal validation [area under the receiver operating characteristic curve range: 0.992-0.999], CheXpert [0.933-0.948], and CIG [0.949-0.951]). The radiologists identified patients from the paired CXRs with a mean accuracy of 0.900 (95% confidence interval: 0.852-0.948), with performance increasing with experience (mean accuracy:group I [0.874], group II [0.904], group III [0.935], and SimChest [0.904]). SimChest achieved non-inferior performance compared to the radiologists (P for non-inferiority: 0.015). The findings of this diagnostic study indicate that DL models can screen for patient misidentification using a pair of CXRs non-inferiorly to human experts.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10278-024-01245-0DOI Listing

Publication Analysis

Top Keywords

patients paired
12
patient misidentification
8
deep learning
8
reader study
8
models identify
8
identify patients
8
human experts
8
patient identification
8
multiple datasets
8
internal validation
8

Similar Publications

Background: In the context of injectable biologic products approved or in development for chronic spontaneous urticaria (CSU), it is important to capture which treatment attributes matter most to patient and what trade-offs patients are willing to make.

Objectives: The CHOICE-CSU study aimed to quantify patient preferences toward injectable treatment attributes among patients with CSU, inadequately controlled by H1-antihistamines.

Methods: This was a two-phase cross-sectional patient preference study in adult patients with a diagnosis of CSU, inadequately controlled by H1-antihistamines.

View Article and Find Full Text PDF

Clinical Trials in Cancer Theranostics with Potential Near-Term Impact on Clinical Practice.

Br J Radiol

January 2025

Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Theranostics has its roots with the first radioiodine therapy for thyroid diseases in about 80 years ago. More recently the field has experienced a remarkable renascence with the regulatory approval of paired imaging and radiopharmaceutical therapy agents in gastroenteropancreatic neuroendocrine tumors and metastatic castration-resistant prostate cancer that are now employed in routine clinical practice. The momentum is strong for identification and testing of new theranostic agents for use in various cancers and finding new clinical incications of the available agents.

View Article and Find Full Text PDF

Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?

Antimicrob Agents Chemother

January 2025

Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Paired baseline and post-exposure isolates from 34 patients who developed ceftolozane-tazobactam (TOL-TAZ) resistance following treatment of multidrug-resistant (MDR) infections were analyzed to determine if ceftolozane with an alternative β-lactamase inhibitor could restore susceptibility. The median baseline TOL-TAZ MIC was 2 mg/L; 88% of post-exposure isolates harbored new mutations. Median MIC fold-increase from baseline was 32-, 24-, 16-, and 6-fold for ceftolozane-tazobactam, ceftolozane-avibactam (AVI), ceftolozane-relebactam (REL), and ceftolozane-durlobactam (DUR), respectively.

View Article and Find Full Text PDF

Objectives: We aimed to determine if shared decision-making (SDM) self-assessment of a standardized patient (SP) scenario was reliable, specifically whether students' communication resulted in each SP-student pair reporting internally consistent final treatment choices. We hypothesized student self-assessment would differ from SP and faculty assessment indicating a need for multisource feedback.

Methods: In this observational case study from 2016-2017, all third-year post-clerkship medical students received evidence-based treatment options for sinusitis and SDM lectures followed by a SP encounter on sinusitis.

View Article and Find Full Text PDF

Background: Acute myocardial infarction (AMI), a subset of acute coronary syndrome, remains the major cause of mortality worldwide. Mitochondrial dysfunction is critically involved in AMI progression, and mitophagy plays a vital role in eliminating damaged mitochondria. This study aimed to explore mitophagy-related biomarkers and their potential molecular basis in AMI.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!